Scientific
MK5 Microarray Data

Affected Genes - Ontology Breakdown - Gene Enrichment - Proteome Analysis
These are the micro-array results of a differential gene expression microarray experiments and the subsequent analysis steps performed on them. The up/down- regulation ratio was obtained by measuring WT cells against MK5 activated cells. See material and methods for technical information as well as the data usage policy.
MK5 Proteome Network Type I Analysis

Type 1 network in which we propagated the absolute log regulation ratio abs(log(r/g)). We used the filtered lowest boundary of the confidence interval for the microarray measurement based and used the high confidence interaction map. Because type-I networks tend to favour highly connected proteins we tested a normalisation scheme in which we would run the network once with real values (the measured column) and once with simulated values where each measured point is set to 1 instead of the actual signal (the expected column). Afterwards we divided the measured value by the expected value. This normalisation scheme works to a certain extend but will lead to a variance that is directly related to the connectivity of each protein. In the end we dropped the use of Type-I networks due to the many technical problems they pose.
Navigation/Query Panel:
Click on the attribute name to hide/unhide it. The green arrows can be used to shift columns left/right. Exact word match is written as =..., regular expressions can be matched with ~.... To select all values larger or equal than use >.... This would be <... for values smaller or equal than. To select all values within a specific range use [...,...].
measured Hugo Gene Rank description expected final
Results: HTML CSV LaTeX
Showing element 51 to 100 of 3206 in total

\def\wcA{0.14285714285714\textwidth}
\def\wcB{0.14285714285714\textwidth}
\def\wcC{0.14285714285714\textwidth}
\def\wcD{0.14285714285714\textwidth}
\def\wcE{0.14285714285714\textwidth}
\def\wcF{0.14285714285714\textwidth}
\begin{longtable}{|c|c|c|c|c|c|}
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
measured\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
Hugo\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
Rank\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
description\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
expected\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
final\vspace{3pt}}\\
\hline
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0196608\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
BPI\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
2159\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
BACTERICIDAL PERMEABILITY-INCREASING PROTEIN PRECURSOR (BPI) (CAP 57). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.0865184\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.227244147\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0196713\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SERPINB10\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
2322\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
BOMAPIN (PROTEASE INHIBITOR 10) (SERPIN B10). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.088691\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.221795898\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0196837\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
LTV1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1907\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.0847765\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.232183447\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0196941\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NUDT12\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1959\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
NUDIX (NUCLEOSIDE DIPHOSPHATE LINKED MOIETY X)-TYPE MOTIF 12. \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.085173\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.231224684\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0197176\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
STARD13\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
2625\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
STAR-RELATED LIPID TRANSFER PROTEIN 13 (STARD13) (START DOMAIN- CONTAINING PROTEIN 13) (46H23.2). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.0938936\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.209999404\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0198288\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MARK2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1466\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
MAP/MICROTUBULE AFFINITY-REGULATING KINASE 2 ISOFORM B; ELKL MOTIF KINASE 1; ELKL MOTIF KINASE. \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.08159\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.243029783\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0198445\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PRMT3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
2013\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
PROTEIN ARGININE N-METHYLTRANSFERASE 3 (EC 2.1.1.-) (FRAGMENT). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.0860464\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.230625569\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0198854\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SERPINB8\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
2328\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
PLASMINOGEN ACTIVATOR INHIBITOR-2 PRECURSOR (PAI-2) (PLACENTAL PLASMINOGEN ACTIVATOR INHIBITOR) (MONOCYTE ARG-SERPIN) (UROKINASE INHIBITOR). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.0896565\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.221795408\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0199527\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SERPINB6\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
2327\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
PLACENTAL THROMBIN INHIBITOR (CYTOPLASMIC ANTIPROTEINASE) (CAP) (PROTEASE INHIBITOR 6) (PI-6). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.0899599\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.221795489\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0199772\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
2324\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
CYTOPLASMIC ANTIPROTEINASE 2 (CAP2) (CAP-2) (PROTEASE INHIBITOR 8) (SERPIN B8). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.0900703\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.221795642\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0199967\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
BRP44\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
3010\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
BRAIN PROTEIN 44. \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.163819\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.122065817\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0200176\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HHATL\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
2598\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.0940277\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.212890457\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0200935\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SERPINB9\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
2321\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
CYTOPLASMIC ANTIPROTEINASE 3 (CAP3) (CAP-3) (PROTEASE INHIBITOR 9) (SERPIN B9). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.0905944\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.22179627\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0202662\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NFYA\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
3114\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
CCAAT-BINDING TRANSCRIPTION FACTOR SUBUNIT B (CBF-B) (NF-Y PROTEIN CHAIN A) (NF-YA) (CAAT-BOX DNA BINDING PROTEIN SUBUNIT A). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.2235\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.09067651\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0202703\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
2773\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
DJ570F3.6 (NOVEL PROTEIN SIMILAR TO LYSOPHOSPHOLIPASE II (LYPLA2)). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.100647\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.201399942\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0203563\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HAS2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1993\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
HYALURONAN SYNTHASE 2 (EC 2.4.1.212) (HYALURONATE SYNTHASE 2) (HYALURONIC ACID SYNTHASE 2) (HA SYNTHASE 2). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.0881799\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.230849661\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0203871\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ARHGAP26\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1622\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
OLIGOPHRENIN-1 LIKE PROTEIN (GTPASE REGULATOR ASSOCIATED WITH FOCAL ADHESION KINASE). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.0850893\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.239596518\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0204267\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
GLI3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
2360\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
ZINC FINGER PROTEIN GLI3. \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.0927234\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.220297142\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0204392\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ABHD3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
944\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
ALPHA/BETA HYDROLASE DOMAIN CONTAINING PROTEIN 3; LUNG ALPHA/BETA HYDROLASE 3. \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.0797142\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.25640601\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0206348\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
LYPLA2P1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
2774\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
LYSOPHOSPHOLIPASE II; ACYL-PROTEIN THIOESTERASE. \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.102457\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.201399612\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0206788\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CLPTM1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
2162\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
CLEFT LIP AND PALATE ASSOCIATED TRANSMEMBRANE PROTEIN 1. \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.0909983\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.227243806\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0207502\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HS3ST2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
2991\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
HEPARAN SULFATE D-GLUCOSAMINYL  3-O-SULFOTRANSFERASE 2; HEPARIN-GLUCOSAMINE 3-O-SULFOTRANSFERASE. \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.153323\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.135336512\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0208556\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RAB37\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
2068\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
RAS-RELATED PROTEIN RAB-37. \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.0908932\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.229451708\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0209707\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
FAM86C\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
2543\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.0977138\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.214613494\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0210051\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HS3ST6\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
2995\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
C439A6.1 (NOVEL PROTEIN SIMILAR TO HEPARAN SULFATE (GLUCOSAMINE) 3-O- SULFOTRANSFERASES) (FRAGMENT). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.155207\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.135336035\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.021031\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MARK1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1462\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
MAP/MICROTUBULE AFFINITY-REGULATING KINASE 1. \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.0865364\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.243030678\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0210454\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HS3ST4\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
2990\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.155504\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.135336712\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0211489\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HECTD1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
874\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
HECT DOMAIN CONTAINING PROTEIN 1 (FRAGMENT). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.081259\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.260265324\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0211896\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
AKT2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1437\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
"RAC-BETA SERINE/THREONINE PROTEIN KINASE (EC 2.7.1.-) (RAC-PK-BETA) (PROTEIN KINASE AKT-2) (PROTEIN KINASE B, BETA) (PKB BETA). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.0870115\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.24352643\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0213112\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
GAD1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1732\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
"GLUTAMATE DECARBOXYLASE, 67 KDA ISOFORM (EC 4.1.1.15) (GAD-67) (67 KDA GLUTAMIC ACID DECARBOXYLASE). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.0899059\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.237038949\vspace{3pt}}\\\hline
\multirow{2}{*}{\parbox{\wcA}{\vspace{3pt}\noindent
0.02137\vspace{3pt}}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1731\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.0901539\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
0.237039108\vspace{3pt}}}\\\cline{2-4}
&\parbox{\wcB}{\vspace{3pt}\noindent
NOSTRIN\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1730\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
NOSTRIN. \vspace{3pt}}&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0213901\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CPA1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1810\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
CARBOXYPEPTIDASE A1 PRECURSOR (EC 3.4.17.1). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.0912429\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.234430295\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0214423\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SLC3A1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1812\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
"NEUTRAL AND BASIC AMINO ACID TRANSPORT PROTEIN RBAT (B(0,+)-TYPE AMINO ACID TRANSPORT PROTEIN) (NBAT) (D2H). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.0914656\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.234430212\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0214512\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TST\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
2641\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
THIOSULFATE SULFURTRANSFERASE (EC 2.8.1.1) (RHODANESE). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.10215\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.209997063\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0214576\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1540\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
DJ1099D15.1 (PUTATIVE DNAJ PROTEIN). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.0887019\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.241906881\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0215242\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
VAMP3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
2735\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
VESICLE-ASSOCIATED MEMBRANE PROTEIN 3 (VAMP-3) (SYNAPTOBREVIN 3) (CELLUBREVIN) (CEB). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.104827\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.205330688\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0215869\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RHOC\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
2636\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
TRANSFORMING PROTEIN RHOC (H9). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.102796\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.209997471\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0217044\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DDOST\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
2999\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
DOLICHYL-DIPHOSPHOOLIGOSACCHARIDE--PROTEIN GLYCOSYLTRANSFERASE 48 KDA SUBUNIT PRECURSOR (EC 2.4.1.119) (OLIGOSACCHARYL TRANSFERASE 48 KDA SUBUNIT) (DDOST 48 KDA SUBUNIT). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.160664\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.135091869\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0217565\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
2541\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.101375\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.214614057\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0218319\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
AKT1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1438\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
RAC-ALPHA SERINE/THREONINE KINASE (EC 2.7.1.-) (RAC-PK-ALPHA) (PROTEIN KINASE B) (PKB) (C-AKT). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.089649\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.24352642\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0218584\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ZC3H12C\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
2141\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.0959445\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.227823377\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0221128\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SDF2L1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1890\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
STROMAL CELL-DERIVED FACTOR 2-LIKE PROTEIN 1 PRECURSOR (SDF2 LIKE PROTEIN 1) (PWP1-INTERACTING PROTEIN 8). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.0950179\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.232722466\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0222862\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TBX19\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
2452\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
T-BOX TRANSCRIPTION FACTOR TBX19 (T-BOX PROTEIN 19). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.102768\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.216859334\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0223215\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HAS3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1991\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
HYALURONAN SYNTHASE 3 (EC 2.4.1.212) (HYALURONATE SYNTHASE 3) (HYALURONIC ACID SYNTHASE 3) (HA SYNTHASE 3). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.0966924\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.230850615\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0223249\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SLC25A13\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
2589\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
"CALCIUM-BINDING MITOCHONDRIAL CARRIER PROTEIN ARALAR2 (SOLUTE CARRIER FAMILY 25, MEMBER 13) (CITRIN). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.104865\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.212891813\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0223435\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ARHGEF3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1527\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
"RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR 3; RHOGEF PROTEIN; 59.8 KDA PROTEIN; EXCHANGE FACTOR FOUND IN PLATELETS AND LEUKEMIC AND NEURONAL TISSUES, XPLN. \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.0922076\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.242317336\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0223509\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CASP3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1829\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
APOPAIN PRECURSOR (EC 3.4.22.-) (CYSTEINE PROTEASE CPP32) (YAMA PROTEIN) (CPP-32) (CASPASE-3) (CASP-3) (SREBP CLEAVAGE ACTIVITY 1) (SCA-1). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.0954818\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.234085449\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0224671\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
LIPM\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1849\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
BA304I5.1 (NOVEL LIPASE) (FRAGMENT). \vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.0962388\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.233451581\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
0.0224883\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ALDH18A1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1681\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
DELTA 1-PYRROLINE-5-CARBOXYLATE SYNTHETASE (P5CS) [INCLUDES: GLUTAMATE 5-KINASE (EC 2.7.2.11) (GAMMA-GLUTAMYL KINASE) (GK); GAMMA-GLUTAMYL PHOSPHATE REDUCTASE (GPR) (EC 1.2.1.41) (GLUTAMATE-5-SEMIALDEHYDE DEHYDROGENASE) (GLUTAMYL-GAMMA-SEMIALDEHYDE DEHYDR\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.0944225\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.238166751\vspace{3pt}}\\\hline
nd{longtable}

Legend:
- Rank is the rank after comparing the two networks

 - Gene is the ensembl human gene identifier measured by 1 or more probes on the microarray

 - Hugo is the bloody hugo identifier as demanded by the BMC Bioinformatics idiots
- http://analysis.yellowcouch.org/